Date published: 2025-10-25

1-800-457-3801

SCBT Portrait Logo
Seach Input

INPP5B Inhibitors

INPP5B inhibitors are a diverse set of chemical compounds that impede the functional activity of INPP5B through various mechanisms affecting the cellular phosphoinositide pools and signaling pathways. Lithium chloride, by inhibiting inositol monophosphatase, leads to inositol depletion and a consequential reduction in IP3 levels, thereby reducing the substrate available for INPP5B, which is responsible for dephosphorylating PI(4,5)P2. Similarly, neomycin sequesters phosphoinositides, diminishing the PI(4,5)P2 accessible to INPP5B. The inhibition of PLC by U-73122 prevents the formation of DAG and IP3, substrates that INPP5B normally acts upon, and perifosine modulates the PI3K/AKT pathway, thereby indirectly decreasing INPP5B substrate levels. Wortmannin and LY 294002, both PI3K inhibitors, disrupt the production of PIP3, affecting the balance of phosphoinositides that INPP5B might regulate. By altering protein phosphorylation states, PAO can indirectly influence INPP5B's interaction with substrates, while edelfosine and miltefosine, both lipid raft disruptors, modify membrane phosphoinositide composition, potentially decreasing INPP5B's substrate accessibility.

In addition to these phosphoinositide-targeting compounds, other inhibitors interfere with cellular structures and mechanisms that indirectly impact INPP5B functionality. Brefeldin A and monensin, both disruptors of the Golgi apparatus, could lead to mislocalization of INPP5B or impair its access to substrate pools due to altered lipid trafficking. This disruption is critical as the Golgi is a central hub for lipid sorting and trafficking, processes integral to maintaining the phosphoinositide substrates that INPP5B dephosphorylates. Propranolol, generally known as a beta-blocker, also has an effect on phospholipid metabolism which may reduce the availability of phosphoinositides necessary for INPP5B's dephosphorylation activity. Collectively, these inhibitors act on diverse but interconnected biochemical pathways, leading to a diminished functional activity of INPP5B by manipulating the availability and localization of its substrates as well as the integrity of cellular structures important for its action.

SEE ALSO...

Product NameCAS #Catalog #QUANTITYPriceCitationsRATING

Lithium

7439-93-2sc-252954
50 g
$214.00
(0)

Lithium chloride acts as an inhibitor of inositol monophosphatase, leading to the depletion of inositol triphosphate (IP3) and subsequently reducing the substrate availability for INPP5B which is involved in the dephosphorylation of phosphatidylinositol (4,5)-bisphosphate (PI(4,5)P2).

Neomycin sulfate

1405-10-3sc-3573
sc-3573A
1 g
5 g
$26.00
$34.00
20
(5)

Neomycin binds to and sequesters phosphoinositides, thereby diminishing the pool of PI(4,5)P2 available for hydrolysis by INPP5B.

Perifosine

157716-52-4sc-364571
sc-364571A
5 mg
10 mg
$184.00
$321.00
1
(2)

Perifosine, an alkylphospholipid, indirectly inhibits INPP5B by modulating the PI3K/AKT pathway and altering phosphoinositide levels in the cell membrane, leading to reduced availability of the substrate for INPP5B.

Wortmannin

19545-26-7sc-3505
sc-3505A
sc-3505B
1 mg
5 mg
20 mg
$66.00
$219.00
$417.00
97
(3)

Wortmannin is a potent inhibitor of phosphoinositide 3-kinases (PI3K), leading to a decrease in phosphatidylinositol (3,4,5)-trisphosphate (PIP3) levels, and indirectly affects INPP5B by altering the phosphoinositide equilibrium.

LY 294002

154447-36-6sc-201426
sc-201426A
5 mg
25 mg
$121.00
$392.00
148
(1)

LY 294002 is another PI3K inhibitor that causes a reduction in PIP3 levels, thus indirectly influencing INPP5B function by disrupting phosphoinositide dynamics within the cell.

Edelfosine

70641-51-9sc-507459
5 mg
$216.00
(0)

Edelfosine is a synthetic alkyl-lysophospholipid that disrupts lipid rafts and may indirectly decrease the functionality of INPP5B by changing the landscape of membrane phosphoinositides.

Miltefosine

58066-85-6sc-203135
50 mg
$79.00
8
(1)

Miltefosine is an alkylphosphocholine that can alter cell membrane composition, potentially leading to reduced substrate availability for INPP5B.

Brefeldin A

20350-15-6sc-200861C
sc-200861
sc-200861A
sc-200861B
1 mg
5 mg
25 mg
100 mg
$30.00
$52.00
$122.00
$367.00
25
(3)

Brefeldin A disrupts Golgi structure and function, which could indirectly impair INPP5B localization and function, as the Golgi is important for lipid trafficking and INPP5B activity.

Monensin A

17090-79-8sc-362032
sc-362032A
5 mg
25 mg
$152.00
$515.00
(1)

Monensin is a polyether that alters Golgi apparatus function and may diminish INPP5B activity by affecting the trafficking and distribution of phosphoinositides.

Propranolol

525-66-6sc-507425
100 mg
$180.00
(0)

Propranolol, a non-selective beta-blocker, has been shown to inhibit phospholipid metabolism, and could indirectly reduce the availability of substrates for INPP5B.